White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Objective Recent studies suggest that white matter hyperintensities (WMH) on MRI, which primarily reflect small vessel cerebrovascular disease, may play a role in the evolution of Alzheimer disease (AD). In a longitudinal study, we investigated whether WMH promote the progression of AD pathology, or alter the association between AD pathology and risk of progression from normal cognition to mild cognitive impairment (MCI). Methods Two sets of analyses were conducted. The relationship between whole brain WMH load, based on fluid-attenuated inversion recovery MRI, obtained in initially cognitively normal participants (n = 274) and time to onset of symptoms of MCI (n = 60) was examined using Cox regression models. In a subset of the participants with both MRI and CSF data (n = 204), the interaction of WMH load and CSF AD biomarkers was also evaluated. Results Baseline WMH load interacted with CSF total tau (t-tau) with respect to symptom onset, but not with CSF β-amyloid 1–42 or phosphorylated tau (p-tau) 181. WMH volume was associated with time to symptom onset of MCI among individuals with low t-tau (hazard ratio [HR] 1.35, confidence interval [CI] 1.06–1.73, p = 0.013), but not those with high t-tau (HR 0.86, CI 0.56–1.32, p = 0.47). The rate of change in the CSF biomarkers over time was not associated with the rate of change in WMH volumes. Conclusion These results suggest that WMH primarily affect the risk of progression when CSF measures of neurodegeneration or neuronal injury (as reflected by t-tau) are low. However, CSF biomarkers of amyloid and p-tau and WMH appear to have largely independent and nonsynergistic effects on the risk of progression to MCI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 1×
“Analyses that included APOE e4 carrier status excluded 6 individuals with the e2/e4 genotype because these alleles have contrasting effects on dementia risk.(22,23)”
BackgroundA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
The overlap between vascular disease and Alzheimer’s disease - lessons from pathology
Attems, J., & Jellinger, K. A. (2014) · BMC Medicine · doi:10.1186/s12916-014-0206-2 · Cited by 739 · cited 2×
“Alzheimer disease (AD) and cerebrovascular disease frequently co-occur among older adults.(1) It remains unclear, however, whether these 2 pathologies independently affect the risk of cognitive impairment, or whether they have synergistic effects on cognitive decline.”
BackgroundBuerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., et al. (2006) · Brain · doi:10.1093/brain/awl269 · Cited by 586
Lee, S., Viqar, F., Zimmerman, M. E., Narkhede, A., Tosto, G., Benzinger, T. L. S., Marcus, D. S., Fagan, A. M., Goate, A., Fox, N. C., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24647 · Cited by 542
Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., Sutphen, C. L., Benzinger, T. L. S., Mintun, M. A., Holtzman, D. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182918ca6 · Cited by 222
Kester, M. I., Goos, J. D. C., Teunissen, C. E., Benedictus, M. R., Bouwman, F. H., Wattjes, M. P., Barkhof, F., Scheltens, P., & van der Flier, W. M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.754 · Cited by 161 · cited 1×
“We also did not observe any associations between baseline CSF biomarker levels and the rate of change in WMH over time, or between baseline WMH volumes and the rate of change in CSF biomarkers, consistent with prior findings.(5,32) However, since both the CSF and the WMHmeasures in this study represent wholebrain meas…”
ResultReview: Tau in biofluids – relation to pathology, imaging and clinical features
Zetterberg, H. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12378 · Cited by 157 · cited 1×
“Elevations in t-tau, by comparison, are more reflective of general levels of neurodegeneration/injury and also seen in other diseases.(27) Our findings are also consistent with neuropathologic studies suggesting that when both AD pathology and cerebrovascular disease are present, AD pathology has the greatest effect o…”
Result
Cited by
Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain
Wingo, A. P., Fan, W., Duong, D. M., Gerasimov, E. S., Dammer, E. B., Liu, Y., Harerimana, N. V., White, B., Thambisetty, M., Troncoso, J. C., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0635-5 · Cited by 161
Anfray, A., Schaeffer, S., Hattori, Y., Santisteban, M. M., Casey, N., Wang, G., Strickland, M., Zhou, P., Holtzman, D. M., Anrather, J., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01757-6 · Cited by 53
Luo, J., Ma, Y., Agboola, F. J., Grant, E., Morris, J. C., McDade, E., Fagan, A. M., Benzinger, T. L. S., Hassenstab, J., Bateman, R. J., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207378 · Cited by 35
Newton, P., the BIOCARD Research Team, Tchounguen, J., Pettigrew, C., Lim, C., Lin, Z., Lu, H., Moghekar, A., Albert, M., & Soldan, A. (2023) · Journal of Alzheimer's Disease · doi:10.3233/jad-220846 · Cited by 23
Self-citationCha, W.-J., Yi, D., Ahn, H., Byun, M. S., Chang, Y. Y., Choi, J.-M., Kim, K., Choi, H., Jung, G., Kang, K. M., et al. (2024) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01417-8 · Cited by 20
“Only a couple of longitudinal studies have investigated a causal relationship between WMH and Aβ using CSF or imaging data, with mixed results in both directions [18–20].”
BackgroundResult
Metadata
- Authors
- Soldan, A., Pettigrew, C., Zhu, Y., Wang, M.-C., Moghekar, A., Gottesman, R. F., Singh, B., Martinez, O., Fletcher, E., DeCarli, C., Albert, M., & for the BIOCARD Research Team
- Venue
- Neurology
- Published
- 2020-03-03
- Volume
- 94
- Issue
- 9
- Pages
- e950-e960
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2998727031
- Cited by
- 84
- References
- 15
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000008864
- The paper
- Soldan, A., Pettigrew, C., Zhu, Y., Wang, M.-C., Moghekar, A., Gottesman, R. F., Singh, B., Martinez, O., Fletcher, E., DeCarli, C., Albert, M., & for the BIOCARD Research Team. (2020). White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0000000000008864
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.